Patients with FeNO<37 ppb (n = 25) Patients with FeNO ≥ 37 ppb(n = 12) ANOVA
  0W 8W p-Value 0W 8W p-Value p-Value
ACQ5, overall score 0.0(0.0-0.2) 0.0(0.0-0.2) 0.2341 0.0(0.0-0.1) 0.0(0.0-0.0) 1.0000 0.7678
FVC, L 3.02(2.43-3.44) 3.12(2.45-3.58) 0.6271 3.47(2.67-4.05) 3.35(2.50-3.87) 0.4769 0.6890
%FVC, % 97.9(88.0-109.6) 98.1(86.7-109.8) 0.5111 115.8(104.6-134.2) 114.6(97.1-132.4) 0.4236 0.7565
FEV1, L 2.36(1.80-2.91) 2.29(1.72-2.79) 0.0591 2.43(1.86-2.97) 2.15(1.78-3.03) 0.4145 0.8900
%FEV1 (% predicted) 88.2(80.6-105.1) 85.9(76.9-104.8) 0.0593 106.2(79.1-112.0) 101.9(72.0-111.0) 0.3329 0.7697
%FEF50%, % 64.0(47.8-102.9) 63.3(46.1-98.0) 0.1137 57.7(40.0-91.9) 49.8(31.4-91.9) 0.2477 0.8567
%FEF75%, % 46.5(34.8-81.1) 44.3(25.7-75.5) 0.0765 37.4(25.8-62.5) 25.5(18.8-69.5) 0.2845 0.8266
PEF variability, % 3.3(2.0-5.7) 3.0(2.0-4.7) 0.1440 2.7(1.8-4.6) 2.9(1.4-5.9) 0.2026 0.8770
Min%Max PEF, % 90.3(87.1-93.0) 91.0(86.1-93.0) 0.9405 90.0(87.8-94.8) 91.5(86.1-95.6) 0.4413 0.2957
FeNO, ppb 20.0(18.0-28.0) 25.5(18.8-34.5) 0.0495 51.5(40.8-57.5) 67.0(33.0-76.0) 0.2298 0.7565
Data are expressed as the medians (interquartile ranges).
Abbreviations: ACQ5: Asthma Control Questionnaire, 5-item version; ANOVA:Analysis Of Variance; FBC:Formoterol/Budenonide Combination; FEF50%:Forced Expiratory Flow at 50% of FVC; FeNO:Fractional Exhaled Nitric Oxide; FEV1:Forced Expiratory Volume in 1 Second; FVC:Forced Vital Capacity; Min%Max PEF:The Lowest PEF Over a Week Expressed as the Percentage of the Highest PEF; PEF:Peak Expiratory Flow.*p <0.05 versus 0 W.
Table 2: Changes in ACQ5, pulmonary functions, and FeNOuntil 8 weeks after stepping down.
Goto home»